Response to the comparison of generic Ritonavir (Ritomune, Cipla) and Lopinavir/Ritonavir Tablets (Lopimune, Cipla) and the abbott brand (Norvir Soft-Gel Capsules and Kaletra Tablets)

Chachad, Siddarth; Gogtay, Jaideep; Malhotra, Geena; Purandare, Shrinivas

doi:10.1002/jps.21852

Journal of Pharmaceutical Sciences

2010

DOI: 10.1002/jps.21852

|View full text |Cite

Response to the comparison of generic Ritonavir (Ritomune, Cipla) and Lopinavir/Ritonavir Tablets (Lopimune, Cipla) and the abbott brand (Norvir Soft-Gel Capsules and Kaletra Tablets)

Siddarth Chachad

Jaideep Gogtay

Geena Malhotra

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Response to the comparison of generic Ritonavir (Ritomune, Cipla) and Lopinavir/Ritonavir Tablets (Lopimune, Cipla) and the abbott brand (Norvir Soft-Gel Capsules and Kaletra Tablets)

Cited by 1 publication

References 2 publications

Comparative Bioavailability of Two Formulations of Biopharmaceutical Classification System (BCS) Class IV Drugs: A Case Study of Lopinavir/Ritonavir

Comparative Bioavailability of Two Formulations of Biopharmaceutical Classification System (BCS) Class IV Drugs: A Case Study of Lopinavir/Ritonavir

Contact Info

Product

Resources

About